
Vijay Shivaswamy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3976481/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocrine Reviews, 2016, 37, 37-61.	20.1	220
2	Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation. International Journal of Endocrinology, 2014, 2014, 1-9.	1.5	46
3	The impact of apathy on glycemic control in diabetes: A cross-sectional study. Diabetes Research and Clinical Practice, 2008, 79, 37-41.	2.8	45
4	A Retrospective Study of Glucagon-Like PeptideÂ1 Receptor Agonists for the Management of Diabetes After Transplantation. Diabetes Therapy, 2020, 11, 987-994.	2.5	30
5	Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats. Translational Research, 2014, 163, 221-231.	5.0	29
6	Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague–dawley rats. Endocrine, 2010, 37, 489-496.	2.3	19
7	Diabetes and Cardiovascular Disease Following Kidney Transplantation. Current Diabetes Reviews, 2011, 7, 221-234.	1.3	19
8	Genetically Targeted Dipeptidyl Peptidase-4 Inhibitor Use in a Patient with a Novel Mutation of MODY type 4. Clinical Medicine Insights: Endocrinology and Diabetes, 2015, 8, CMED.S31926.	1.9	17
9	Metformin Improves Immunosuppressant Induced Hyperglycemia and Exocrine Apoptosis in Rats. Transplantation, 2013, 95, 280-284.	1.0	16
10	Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules. Journal of the Endocrine Society, 2021, 5, bvab148.	0.2	12
11	A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. Journal of Diabetes and Its Complications, 2020, 34, 107494.	2.3	10
12	Tacrolimus and Sirolimus Induce Reproductive Abnormalities in Female Rats. Transplantation, 2011, 91, 1333-1339.	1.0	9
13	Management of the Hospitalized Transplant Patient. Current Diabetes Reports, 2015, 15, 19.	4.2	9
14	Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review. Patient Preference and Adherence, 2016, Volume 10, 1999-2006.	1.8	6
15	An altered spatiotemporal gait adjustment during a virtual obstacle crossing task in patients with diabetic peripheral neuropathy. Journal of Diabetes and Its Complications, 2019, 33, 182-188.	2.3	6
16	Post-transplant diabetes: diagnosis and management. Minerva Endocrinology, 2018, 43, 198-211.	1.1	5
17	Dyslipidemia Can Be Controlled in Diabetic as Well as Nondiabetic Recipients After Kidney Transplant. Transplantation, 2008, 85, 1270-1276.	1.0	4
18	Adrenal oncoctyoma of uncertain malignant potential: a rare etiology of adrenal incidentaloma. Clinical Case Reports (discontinued), 2016, 4, 303-304.	0.5	4

VIJAY SHIVASWAMY

#	Article	IF	CITATIONS
19	A retrospective review of insulin requirements in patients using U-500 insulin hospitalized to a Veterans Affairs Hospital. Journal of Diabetes and Its Complications, 2017, 31, 874-879.	2.3	3
20	Bronchial Carcinoid and Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4252-4253.	3.6	0
21	Catecholamine Crisis Precipitated by Intra-Articular Glucocorticoid Administration in a Patient with Paraganglioma. AACE Clinical Case Reports, 2015, 1, e265-e268.	1.1	Ο
22	Impact of Blood Glucose Reporting on Glycemic Variability in Veterans With Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1348-1349.	2.2	0
23	The Impact of Diabetic Peripheral Neuropathy on Patient's Balance Ability and Stepping Strategy a Virtual Obstacle Crossing Study. Archives of Physical Medicine and Rehabilitation, 2020, 101, e108-e109.	0.9	0
24	Tissue Specific Actions of the Ept1, Ept2, Ept6 and Ept9 Genetic Determinants of Responsiveness to Estrogens in the Rat Biology of Reproduction, 2008, 78, 308-308.	2.7	0
25	SAT-121 Immediate Dysglycemia After Pancreatic Resection: Prevalence and Risk Factors. Journal of the Endocrine Society, 2019, 3, .	0.2	Ο